Scientific publications

Intracellular Activity of Antibiotics against Coxiella burnetii in a Model of Activated Human THP-1 Cells
F. Peyrusson, A. O. Whelan, M. G. Hartley, I. H. Norville, S. V. Harding, F. Van Bambeke
Antimicrob Agents Chemother. 2021; 65(12)

Uropathogenic Escherichia coli Shows Antibiotic Tolerance and Growth Heterogeneity in an In Vitro Model of Intracellular Infection
I. Kerkez, P. M. Tulkens, T. Tenson, F. Van Bambeke, M. Putrins
Antimicrob Agents Chemother. 2021, 65(12)

Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever
M. G. Hartley, I. H. Norville, M. I. Richards, K. B. Barnes, K. R. Bewley, J. Vipond, E. Rayner, A. Vente, S. J. Armstrong, S.V. Harding
Front. Microbiol. 2021; 10

Finafloxacin Is an Effective Treatment for Inhalational Tularemia and Plague in Mouse Models of Infection
K. B. Barnes, M. I. Richards, T. R. Laws, A. Nunez, J. E. Thwaite, C. Bentley, S. V. Harding
Antimicrob Agents Chemother. 2021, 65(6) 

Early Clinical Assessment of the Antimicrobial Activity of Finafloxacin Compared to Ciprofloxacin in Subsets of Microbiologically Characterized Isolates
A. Vente, C. Bentley, M. Lückermann, P. Tambyah and A. Dalhoff
Antimicrob Agents Chemother. 2018 Mar 27; 62(4)

Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections
F. M. E. Wagenlehner, M. Nowicki, C. Bentley, M. Lückermann, S. Wohlert, C. Fischer, A. Vente, K. Naber and A. Dalhoff
Antimicrob Agents Chemother. 2018 Mar 27; 62(4)

Population Pharmacokinetics of Finafloxacin in Healthy Volunteers and Patients with Complicated Urinary Tract Infections
M. Taubert, M. Lückermann, A. Vente, A. Dalhoff and U. Fuhr
Antimicrob Agents Chemother. 2018 Mar 27; 62(4)

Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance
L. B. Randall, E. Georgi, G. H. Genzel and H. P. Schweizer
J. Antimicrob Chemother. 2017 Apr; 72(4):1258–1260 

Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei
K. B. Barnes, K. A. Hamblin, M. I. Richards, T. R. Laws, A.Vente, H. S. Atkins and S. V. Harding
Antimicrob Agents Chemother. 2017 Jun 27; 61(7)

Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers
M. Taubert, J. Chiesa, M. Lückermann, C. Fischer, A. Dalhoff and U. Fuhr
Antimicrob Agents Chemother. 2017 Sep 22; 61(10)

Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-ß-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections
A. Dalhoff, S. Schubert and A. Vente
Antimicrob Agents Chemother. 2017 Apr 24; 61(5)

High Efficacy of Finafloxacin on Helicobacter pylori Isolates at pH 5.0 Compared with That of Other Fluoroquinolones
J. W. Lee, N. Kim, R. H. Nam, J. M. Kim, J. Y. Park, S. M. Lee, J. S. Kim, D. H. Lee and H. C. Jung
Antimicrob Agents Chemother. 2015 Dec; 59(12):7629–7636 

Finafloxacin for the treatment of urinary tract infections
R. Bartoletti, T. Cai, G. Perletti, F. M. E. Wagenlehner and T. E. Bjerklund Johanse
Expert Opin Investig Drugs. 2015; 24(7):957-63 

Activity of the investigational fluoroquinolone finafloxacin and seven other antimicrobial agents against 114 obligately anaerobic bacteria
G. H. Genzel, W. Stubbings, C. S. Stîngu, H. Labischinski and R. Schaumann
Int J Antimicrob. 2014; 44:420–423 

Urinary Pharmacokinetics and Bactericidal Activity of Finafloxacin (200 and 800 mg) in Healthy Volunteers Receiving a Single Oral Dose
F. M. E. Wagenlehner, C. M. Wagenlehner, B. Blenk, H. Blenk, S. Schubert, A. Dalhoff and K. G. Naber
Chemotherapy 2011; 57:97–107

In Vitro Spectrum of Activity of Finafloxacin, a Novel, pH-Activated Fluoroquinolone, under Standard and Acidic Conditions
W. Stubbings, P. Leow, G. C. Yong, F. Goh, B. Körber-Irrgang, M. Kresken, R. Endermann and H. Labischinski
Antimicrob Agents Chemother. 2011 Sept; 4394–4397 

Human Pharmacokinetics and Safety Profile of Finafloxacin, a New Fluoroquinolone Antibiotic, in Healthy Volunteers
H. Patel, A. Andresen, A. Vente, H.-D. Heilmann, W. Stubbings, M. Seiberling, L. Lopez-Lazaro, R. Pokorny and H. Labischinski
Antimicrob Agents Chemother. 2011 Sept; 55(9):4386-4393

Comparative in vitro activity of finafloxacin against staphylococci displaying normal and small colony variant phenotypes
E. A. Idelevich, A. Kriegeskorte, W. Stubbings, B. C. Kahl, G. Peters and K. Becker
J Antimicrob Chemother. 2011; 66:2809-2813 

Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila
S. Lemaire, F. Van Bambeke and P. M. Tulkens
Int J Antimicrob. 2011; 38:52–59 

Comparative In Vitro Activities of the Novel Antibacterial Finafloxacin against selected Gram-Positive and Gram-Negative Bacteria Tested in Mueller-Hinton Broth and Synthetic Urine
A. Dalhoff, W. Stubbings and S. Schubert
Antimicrob Agents Chemother. 2011; 55:1814-1818 

Activity of the Investigational Fluoroquinolone Finafloxacin against Ciprofloxacin-Sensitive and -Resistant Acinetobacter baumannii Isolates
P. G. Higgins, W. Stubbings, H. Wisplinghoff and H. Seifert
Antimicrob Agents Chemother. 2010; 54:1613-1615 

Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance
N.-C. Emrich, A. Heisig, W. Stubbings, H. Labischinski and P. Heisig
J Antimicrob Chemother. 2010; 65:2530–2533

The Lipopeptide Antibiotic Friulimicin B Inhibits Cell Wall Biosynthesis through Complex Formation with Bactoprenol Phosphate
T. Schneider, K. Gries, M. Josten, I. Wiedemann, S. Pelzer, H. Labischinski and H.-G. Sahl
Antimicrob Agents Chemother. 2009; 53:1610-1618 

Daptomycin versus Friulimicin B: In-Depth profiling of Bacillus subtilis Cell Envelope Stress Responses
T. Wecke, D. Zühlke, U. Mäder, S. Jordan, B. Voigt, S. Pelzer, H. Labischinski, G. Homuth, M. Hecker and T. Mascher
Antimicrob Agents Chemother. 2009; 53:1619-1623

Prospects and challenges in anti-infective research and development: new drugs and approaches.
H. Labischinski and H. Ruebsamen-Waigmann
Current Opinion in Pharmacology. 2008; 8(5):519-521